Translating Molecular Discoveries into New Therapies for Pulmonary Arterial Hypertension  

Oleh:

Raharjo, Sunu Budhi ; Sakidjan, Indriwanto

Jenis: Article from Journal - ilmiah nasional - tidak terakreditasi DIKTI
Dalam koleksi: Cermin Dunia Kedokteran vol. 38 no. 03/184 (Apr. 2011), page 167-172.
Topik: Pathogenesis; hypoxic pulmonary vasoconstriction; Pulmonary hypertension
Fulltext: 05_184Translatingmolecular.pdf (575.01KB)

Ketersediaan

Perpustakaan FK Nomor Panggil: C04.K.2011 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Many of the drugs currently in use for pulmonary arterial hypertension (PAH) were based on the vasodilator hypothesis in PAH therapeutics. These include parenteral prostacyclin analogues, oral endothelin-receptor antagonists, and oral phosphodiesterase type 5 inhibitors. Our understanding of the factors involved in the pathogenesis of PAH has evolved dramatically over the past decade and has led to the development of newer therapeutic strategies that target these processes. This review will address the cellular and molecular processes implicated in clinical, genetic, and experimental studies as underlying pulmonary vascular abnormalities associated with PAH.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali